Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Caffeine Adjuvancy Study Acetaminophen-Only Arm Unnecessary – FDA

This article was originally published in The Tan Sheet

Executive Summary

An acetaminophen-only treatment arm in Bristol-Myers Squibb's planned clinical study on the efficacy of different caffeine doses in analgesic adjuvancy is unnecessary, FDA says in a recent letter
Advertisement

Related Content

Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
BMS caffeine study
BMS caffeine study
BMS caffeine study
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
Caffeine Dose Response Study To Support Category I Status Proposed By BMS
OTC analgesic 65 mg caffeine limit "not supported" by the record, Bristol-Myers tells FDA.

Topics

Advertisement
UsernamePublicRestriction

Register

PS093654

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel